^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastrointestinal Cancer

    1d
    PROPERTY: Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Placebo During Oxaliplatin Based Chemotherapy (clinicaltrials.gov)
    P=N/A, N=73, Completed, Nantes University Hospital | Active, not recruiting --> Completed | N=110 --> 73
    Trial completion • Enrollment change
    |
    oxaliplatin
    1d
    Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases (clinicaltrials.gov)
    P2, N=134, Recruiting, Brigham and Women's Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    2d
    GustaborRCT: Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention (clinicaltrials.gov)
    P=N/A, N=198, Not yet recruiting, Wuerzburg University Hospital
    New trial
    2d
    A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, Ruijin Hospital
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1)
    |
    KRAS mutation • NRAS mutation • RAS mutation • HRAS mutation • KRAS G12 • NRAS G12
    3d
    The NIPA Study Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtients (clinicaltrials.gov)
    P3, N=370, Suspended, University Hospital, Brest | Trial completion date: Sep 2026 --> Apr 2028 | Recruiting --> Suspended | Trial primary completion date: Mar 2026 --> Oct 2027
    Trial completion date • Trial suspension • Trial primary completion date
    3d
    Clinicopathological features and immune checkpoint expression patterns in dMMR early gastric cancer: a retrospective pilot study. (PubMed, BMC Cancer)
    These findings highlight the heterogeneity of immune checkpoint expression patterns and provide preliminary, hypothesis-generating insights into variability in response to PD-1/PD-L1 blockade.
    Retrospective data • Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    3d
    NAT10 promotes colon cancer progression by enhancing predicted N4-acetylcytidine modification of Notch2 mRNA. (PubMed, Discov Oncol)
    NAT10 promotes colon cancer progression in an enzymatic activity‑dependent manner by enhancing predicted ac4C modification of Notch2 mRNA to stabilize its expression. This study reveals a novel NAT10/ac4C/Notch2 regulatory axis and provides potential therapeutic targets for colon cancer.
    Journal
    |
    NOTCH2 (Notch 2)
    3d
    SORA-RT: EVALUATION OF THE BENEFITS OF SOPHROLOGY FOR PATIENTS UNDERGOING RADIOTHERAPY (clinicaltrials.gov)
    P=N/A, N=54, Not yet recruiting, Clinique Pasteur Lanroze
    New trial
    3d
    AI for Onsite Cytology Evaluation in Endoscopic Ultrasound (clinicaltrials.gov)
    P=N/A, N=136, Active, not recruiting, Orlando Health, Inc. | Recruiting --> Active, not recruiting | N=200 --> 136 | Trial completion date: Oct 2027 --> Dec 2026 | Trial primary completion date: Dec 2026 --> Apr 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    3d
    Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events (clinicaltrials.gov)
    P=N/A, N=750, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date • Adverse events
    3d
    Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei (clinicaltrials.gov)
    P=N/A, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    3d
    Molecular mechanisms of KMT2C alterations in gastrointestinal cancers: enhancer network destabilization, lineage plasticity, and clinical translation. (PubMed, Front Immunol)
    In this review, we integrate evidence from hepatocellular carcinoma, pancreatic ductal adenocarcinoma, cholangiocarcinoma, colorectal cancer, gastric cancer, esophageal cancer, and gallbladder cancer within a unified framework that links KMT2C domain architecture to enhancer-network destabilization, phenotypic state transitions, and clinical manifestations. We further propose a functional evaluation paradigm that reframes discrete KMT2C variants as graded states of epigenetic deficiency, coupled with a closed-loop validation strategy integrating tissue-based profiling, liquid biopsy monitoring, and spatial multi-omics analyses.
    Review • Journal • Tumor mutational burden • PARP Biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • KMT2C (Lysine Methyltransferase 2C) • CHEK1 (Checkpoint kinase 1) • DRD (DNA Repair Deficiency)
    |
    DDR